Our Mission
Transform oncology with AI to fast-track life-saving treatments.
Inka Health is pioneering the use of advanced AI-driven analytics and real-world multimodal data to revolutionize clinical research and drug development.
We integrate cutting-edge technologies with rigorous methodologies to deliver actionable insights that drive innovation and precision in oncology.
Our commitment: empowering healthcare advancements with clarity and precision.
Leadership
Paul Arora, PhD
Co-Founder & Scientific Advisor
Paul Arora is Co-Founder of Inka Health and an Adjunct Professor at the University of Toronto. He is an expert in epidemiology, specializing in real-world evidence, health outcomes, and causal inference. He has led numerous large-scale consulting projects. He previously founded Lighthouse Outcomes (acquired).
Alind Gupta, PhD
Co-Founder & Chief Scientific Officer
Alind Gupta is CSO at Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Winson Cheung, MD
Co-Founder & Medical Advisor
Winson Y. Cheung is a Full Professor at the University of Calgary and an expert in medical oncology and real-world evidence. With 15+ years in cancer research, he has published over 300 scientific papers and secured over $20M in research funding, specializing in health outcomes and real-world evidence generation in oncology.
Steven Jones, PhD
Scientific Advisor
Steven Jones is Head of Bioinformatics and Co-Director of the Genome Sciences Centre in Vancouver, and Distinguished Scientist at the BC Cancer Research Institute. He is among the world’s most highly cited researchers in his field, with pioneering contributions to bioinformatics and cancer genomics.
Strategic Advisors
James Orbinski, MD
James is a globally renowned humanitarian, scholar, and Officer of the Order of Canada. He is the Founding Director of York University's Dahdaleh Institute for Global Health Research and former International Council President of Médecins Sans Frontières (Doctors Without Borders), where he accepted the Nobel Peace Prize on behalf of the organization in 1999.
Edward Mills, PhD
Ed Mills is the co-founder of MTEK Sciences and Redwood Outcomes, both successfully acquired by major industry players. He is a principal investigator of multiple adaptive platform trials and large-scale studies and has authored over 550 peer-reviewed papers in leading journals, including NEJM, The Lancet, and JAMA.
Kristian Thorlund, PhD
Kristian is the co-founder of Redwood Outcomes, MTEK Sciences (both acquired), and rAire, as well as the founder of Biospark.ai. A leading biostatistician specializing in Bayesian methods, he is a Clarivate Analytics Highly Cited Researcher, recognized for his impactful contributions to the field.
Our Partners
Our Strengths
Partnership
Enduring Relationships
Dedicated Partners
More than service providers, we commit to building long-term, sustainable relationships.
Customized Solutions
Tailoring our approach to meet the unique needs of each client.
Partner-Centric
Focused on delivering bespoke strategies that ensure collaborator satisfaction and success.
Confidence
Excellence in Methods
Superior Analytics
Instilling confidence with top-tier, transparent methods.
Evidence-Based
Leveraging ITC and real-world evidence for impactful insights.
Reliability & Impact
Ensuring our solutions are both dependable and effective.
Data Agnosticism
Flexible Strategies
Versatility in Data
A specialized approach means we can work with diverse data sources, ranging from RCTs to industry access programs.
​
High Standards
Transparency and rigor in all analytics processes.
Effective Handling
Ensuring adept management of various data types for comprehensive insights. We welcome any and all data provided by collaborators.
Innovation
Strategic Integration of AI
Innovative AI Use
Rooted in innovative, solution-oriented AI applications for analytics.
Focus on Causal Inference
Emphasizing the judicious use of AI to derive authentic insights from real-world data.
Distinctive Methods
Setting our approaches apart with advanced, credible analysis techniques.
Quality
Adherence to Best Practices
Strictly following the latest approaches in RWE and ITC, ensuring top-tier analytics quality.
Regulatory Alignment
In line with NICE, FDA, ISPOR, and CADTH guidelines for excellence in study design and reporting.
Quality Assurance
Commitment to the highest standards in all analytical processes.
Speed
Accelerated Analytics
Utilizing advanced automation for swift insights, delivering results in half the traditional time.
Investment in Innovation
Embracing automation and machine learning for efficient decision-making.
Impact on Healthcare
Ensuring timely decisions that significantly enhance patient outcomes.
Leadership
Thought Leadership
Boasting over 500 published scientific papers by our founding and advisory team.
Methodological Innovation
At the cutting edge with techniques like target trial emulation and Bayesian borrowing.
Accurate Insights
Providing reliable insights through advanced methodologies.
Collaborator Testimonials
"The team's profound understanding of intricacies surrounding real-world evidence and application of cutting-edge methodologies has greatly contributed to the field."
"Winson and team have always been my first port of call for invaluable guidance on implementing innovative methods to enhance the credibility and acceptance of real-world evidence (RWE). The team's profound understanding of the intricacies surrounding real-world evidence and application of cutting-edge methodologies has greatly contributed to the field, showing how RWE can meet the stringent standards set by HTA and payer stakeholders."
- Global Head Real-World Evidence & Market Access at a large-cap pharmaceutical company
Scientific Advisors
Theodore (Ted) Witek
Public Health Policy
Ted Witek served as former President and CEO of Boehringer Ingelheim Canada and sat on the Board of Directors of Innovative Medicines Canada. He is a Full Professor at the University of Toronto and has served on boards and committees, including the American Thoracic Society and the Ontario Health Innovation Council.
Eran Bendavid, MD, MS
Causal Inference and Health Economics
Eran Bendavid is an Associate Professor of Medicine at Stanford University. He specializes in the application of causal inference methods and population health in developing countries. His research explores the effects of economic, political, and natural environments on population health, with a clinical focus on Infectious Diseases.
Kelvin Chan, MD, PhD
Clinical Oncology and Biostatistics
Dr. Kelvin Chan, a medical oncologist at Sunnybrook Odette Cancer Centre and a professor at the University of Toronto, specializes in GI and head and neck oncology. His research spans health services, health technology assessment, and cost-effectiveness analyses, and he plays a key role in cancer drug reimbursement.
Darren Brenner, PhD
Real-World & Molecular Epidemiology
Dr. Darren Brenner is an Associate Professor and cancer epidemiologist at the University of Calgary. He focuses on the intersection of lifestyle, genetics, and molecular pathways in cancer development leading studies on biomarker utility in cancer risk prediction and the impact of lifestyle on molecular pathways in various cancers.
Rebecca Hancock Howard, PhD
Health Economics
Rebecca Hancock Howard is an Adjunct Professor in health economics at the Institute for Health Policy, Management and Evaluation, University of Toronto. She leads independent consulting projects at the Accessing Centre for Expertise and serves as an advisory committee member on Ontario’s Committee to Evaluate Drugs.
Audrey Beliveau, PhD
Bayesian Statistics
Dr. Audrey Beliveau, Assistant Professor at the University of Waterloo, specializes in Bayesian hierarchical modeling with applications in ecology and epidemiology. Her research integrates multiple data sources, emphasizing interdisciplinary collaborations in statistical ecology and network meta-analysis.
Emma Mackay, MA, MSc
Bayesian Statistics
Emma Mackay, MA, MSc, is a statistician specializing in Bayesian methods. Her work has focused on applying Bayesian borrowing to address the challenges of evaluating efficacy in rare disease settings. She has extensive experience in survival modelling, synthetic control arms, and population-adjusted indirect comparisons.
Matt Warkentin, PhD
Real-World and Molecular Oncology
Dr. Matthew Warkentin is a molecular epidemiologist with a decade of expertise in cancer research and machine learning. His work focuses on using big data and AI on medical images, for cancer detection and treatment. He advocates for open-source science and contributes to R and Python programming communities.
Dan Harris, PhD
Pharmacoepidemiology & RWE
Dr. Daniel Harris is a Senior Research Scientist at Brown University School of Public Health with a strong background in pharmacoepidemiology. His research leverages claims data to explore drug utilization, safety, and effectiveness across large populations, employing multivariate statistics and machine learning.
Oscar Correa
Digital Engagement and Data Visualization
Oscar Correa, Managing Partner and Director of Development at Eviviz, brings over 25 years of tech industry experience, focusing on client engagement and project management. His expertise lies in "Holistic Design" in information technology, emphasizing interconnected systems in real-life applications.